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Identity 
Other names: bone metastasizing renal tumor of 
childhood 
Clinics and pathology 
Disease  
Clear cell sarcoma of the kidney (CCSK) is a malignant 
renal tumor of childhood with a propensity to 
metastasize to bone and other organs. This tumor may 
also recur many years after its initial diagnosis. The 
average age at diagnosis is 2-4 years. CCSK is 
unrelated to the clear cell sarcoma of the soft tissue, 
also known as malignant melanoma of soft parts. 
Extrarenal tumors histologically identical to CCSK 
have been reported in rare instances. This tumor may 
be confused with other pediatric renal tumors including 
blastema-predominant Wilms' tumor, malignant 
rhabdoid tumor, and cellular mesoblastic nephroma. 





The tumor is composed of undifferentiated cells as 
illustrated by its relative lack of immunohistochemical 
reactivity. Its gene expression profile with a lack of 
WT-1 mRNA transcripts and elevated levels of IGF-2 
mRNA further suggest that the tumor arises from an 
undifferentiated renal stem cell. Most studies fail to 
implicate the involvement of the p53 tumor suppressor 
gene. 
Epidemiology 
CCSK comprises 5 percent of primary pediatric renal 
tumors with the peak incidence in the second year of  
life; however, patients' ages have ranged from 2 months 
to 54 years. Adult cases are extraordinarily rare. CCSK 
does not appear to be associated with genetic 
syndromes like Wilms' tumor (i.e. WAGR, Beckwith-
Wiedemann, and Denys-Drash syndromes). Males 
appear to be more commonly affected than females. 
The National Wilms' Tumor Study (NWTS) has 
classified CCSK as one of the most common of the 
prognostically unfavorable histology tumors (others 
being anaplastic Wilms' tumor and malignant rhabdoid 
tumor of the kidney). 
Clinics 
The usual presentation of CCSK is a child with a flank 
mass with or without hematuria much like the typical 
signs and symptoms associated with Wilms' tumor. 
Abdominal pain and fever may also occur. In some 
instances, patients present with pathologic fractures due 
to metastatic tumor. 
Pathology 
Grossly, the tumor arises within the renal medulla has a 
mass of up to 3,000 grams. On cut section, the tumor is 
usually white-tan to gray and has a firm texture and is 
sharply defined from the surrounding renal 
parenchyma. Histologically, the classical CCSK 
(features present at least focally in over 90% of tumors) 
is composed of nests and cords of cells with scant 
cytoplasm and high nuclear-cytoplasmic ratios. The 
tumor has a prominent vascular network that may be 
highlighted with Ulex Europeous I lectin or 
monoclonal antibodies specific for factor VIII or CD31. 
Adundant collagenous (sclerotic) extracellular matrix 
material is also a common finding in classical CCSK. 
The nuclei are characterized by a fine chromatin pattern 
and mitotic figures are generally rarely identified. 
Isolated nephrons are entrapped by the tumor. CCSK 
may be confused with Wilms' tumor, mesoblastic 
nephroma, and malignant rhabdoid tumor of the 
kidney. 
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Several histologic variants of CCSK are recognized. 
The most common variant is the myxoid CCSK. This 
histology features diffuse accumulation of 
mucopolysaccharide matrix material between tumor 
cells sometimes creating a cystic appearance. The 
sclerosing variant of CCSK is characterized by 
prominent collagen bundles that may isolate single or 
small groups of tumor cells in a dense matrix that m y 
become hyalinized. The cellular pattern of CCSK is 
characterized by less extracellular matrix material 
between cells with overlapping of nuclei, a feature that 
may lead to confusion with a blastemal predominant 
Wilms' tumor or primitive neuroectodermal tumor. 
Mitotic activity is usually increased in this variant. The 
epithelioid CCSK variant may be confused with 
nephroblastoma due to condensation of tumor cell 
cords. The palisading pattern is described as having 
spindle cell nuclei in parallel linear arrays alternating 
with nuclear free zones, a feature that resembles 
Verocay bodies of schwannomas. The spindle cell and 
storiform patterns are relatively uncommon. Anaplasia 
is a rare finding in CCSK (3% of cases), and is 
characterized by the presence of enlarged, 
hyperchromatic polypoid nuclei with multipolar mitotic 
figures. The nuclear accumulation of p53 in anaplastic 
tumors is thought to represent evidence of p53 gene 
mutation, a finding that has been well-documented in 
anaplastic Wilms' tumors. The frequency of different 
CCSK variants is listed below: 
- Myxoid pattern (50%); 
- Sclerosing pattern (35%); 
- Cellular pattern (26%); 
- Epithelioid pattern (trabecular or acinar type) (13%); 
- Palisading (verocay-body) pattern (11%); 
- Spindle cell pattern (7%); 
- Storiform pattern (4%); 
- Anaplastic pattern (2.6%). 
Immunohistochemistry is rarely informative in CCSK. 
Immunoreactivity for the intermediate filament 
vimentin is usually present, however, reactivity with 
most other proteins including epithelial markers are 
negative. 
Like other renal tumors of childhood, CCSK is staged 
by the National Wilms' Tumor Study staging scheme as 
follows:  
Stage I (25% of CCSK): For stage I tumors, 1 or more 
of the following criteria must be met: 
Tumor is limited to the kidney and is completely 
excised. 
The surface of the renal capsule is intact. 
The tumor is not ruptured or biopsied (open or needle) 
prior to removal. 
No involvement of renal sinus vessels. 
No residual tumor apparent beyond the margins of 
excision. 
Stage II (37% of CCSK): For Stage II tumors, 1 or 
more of the following criteria must be met: 
Tumor extends beyond the kidney but is completely 
excised. 
No residual tumor apparent at or beyond the margins of 
excision. 
Any of the following conditions may also exist: 
Tumor involvement of the blood vessels of the renal 
sinus and/or outside the renal parenchyma. 
The tumor has been biopsied prior to removal or thee 
is local spillage of tumor during surgery, confined to 
the flank. 
Stage III (34% of CCSK): For Stage III tumors, 1 or 
more of the following criteria must be met: 
Unresectable primary tumor. 
Lymph node metastasis. 
Positive surgical margins. 
Tumor spillage involving peritoneal surfaces either 
before or during surgery, or transected tumor thrombus. 
Stage IV (4% of CCSK): defined as the presence of 
hematogenous metastases (lung, liver, bone, or brain), 
or lymph node metastases outside the abdomenopelvic 
region. 
Stage V (not yet reported for CCSK): defined as 
bilateral renal involvement at time of initial diagnosis. 
Treatment 
Treatment of CCSK generally involves surgical 
intervention coupled with radiation and chemotherapy. 
CCSK commonly responds poorly to treatment with 
vincristine and actinomycin alone, but the addition of 
doxorubicin to chemotherapy regimens has improved 
survival rates. In the NWTS-5 protocol, patients with 
all stages of CCSK are treated with the same regimen 
used in patients who have Wilms tumor with diffuse 
anaplasia with the exception of stage I tumors. This 
treatment protocol is comprised of radical nephrectomy 
followed by radiotherapy and chemotherapy with 
cyclophosphamide, etoposide, vincristine, and 
doxorubicin for 24 weeks. 
Prognosis 
The prognosis for CCSK, particularly for low stage 
tumors, has improved with the addition of doxorubicin 
to chemotherapy regimens with a 66% reduction in 
overall mortality. Stage-dependent six-year survival s 
97% for stage I tumors, 75% for stage II tumors, 77% 
for stage III tumors, and 50% for stage IV tumors. 
Patients with tumors without areas of necrosis have  
more favorable prognosis. Twenty-nine percent of 
patients with CCSK have lymph node metastases at the 
time of diagnosis, and bone metastasis is the most 
common form of relapse. Metastatic lesions have also
been reported in the liver, brain, soft tissue sites, and 
lung with more unusual metastases to the skeletal 
muscle, testis, and salivary gland. Relapses of CCSK as 
many as 10 years after original diagnosis have been 
reported. 
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(A) Hemisection of kidney demonstrating large tan-yellow mass characteristic of CCSK. (B) Histologic section of CCSK characterized by 
hyperchromatic cells with high nuclear-cyto-plasmic ratios and abundant extracellular matrix material. (C) p53 immunochemistry with 
only rare cells showing nuclear accumulation of protein. 
 
Cytogenetics 
Note: Only a small number of CCSK cases have been 
described cytogenetically. A clonal reciprocal 10;17 
translocation t(10;17)(q22;p13) in CCSK was first 
reported in 1989. A CCSK with a complex karyotype 
including trisomy 9, deletions of chromosomes 16 and
22, and loss of chromosome 1p13 has been reported. In 
the same case, an interstitial deletion of chromosoe 
14 was reported: del(14)(q23). One of two 
'sarcomatous Wilms' tumors' also contained a 
t(10;17)(q11;p12) as a part of an abnormal karyotype. 
Three of four other patients with CCSK were normal 
whereas one patient harbored a t(2;22)(q21;q11). 
Comparative genomic hybridization analysis of CCSK 
has documented quantitative chromosomal 
abnormalities in only 4 of 30 CCSK cases. These four
cases included a gain of chromosome 1q and loss of 
10q, gain of 1q and loss of terminal 4p, gain of 19p, 
and loss of chromosome 19. Later, another CCSK with
a t(10;17)(q22;p13) was reported. 
Of five patients reviewed at this institution, karyot pes 
were available for four of these. One patient had a 
clonal balanced translocation 10;17 and an interstiial  
 
 
deletion of the long arm of chromosome 14 as follows:  
46, XY, t(10;17)(q22;p13)del(14)(q24.1q31.1).Three 
other patients had normal karyotypes. Fluorescent in-
situ hybridization using a p53 probe was employed on 
the same cells harboring the clonal translocation above. 
This study documented the presence of two p53 signal  
on chromosome 17 indicating the absence of deletion 
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Genes involved and Proteins 
Note: No gene has been implicated in the pathogenesis 
of CCSK. However, given the recurrent finding of 
clonal balanced translocations involving 
t(10;17)(q22;p13), gene(s) located within these regions 
may be related to CCSK pathogenesis. The 
chromosome 17p13 locus harbors the TP53 tumor 
suppressor gene, but several studies have failed to 
implicate mutations of p53 in CCSK. Tumor suppressor 
and oncogenes present on chromosome 10q22 include 
LCX and TET1. Both of these genes are involved in 
fusion gene products in acute myeloid leukemias. 
Tumor suppressor and/or oncogenes located in the 
deleted region of chromosome 14q24.1q31.1 include 
CHES1, a member of the forkhead family of 
transcription factors involved in cell cycle checkpoint 
control, hREC2, a gene encoding a protein with amino 
acid homology to a RAD51 involved in DNA double 
strand break repair, MAP3K9 or mitogen activated 
protein kinase, the MAX transcription factor, placental 
growth factor (VEGF-related protein), and 
transforming growth factor beta-3. 
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